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Abstract  
PEGylated graphene oxide (GO) has shown potential as NIR converting agent to produce local heat 
useful in breast cancer therapy, since its suitable photothermal conversion, high stability in 
physiological fluids, biocompatibility and huge specific surface. GO is an appealing nanomaterial for 
potential clinical applications combining drug delivery and photothermal therapy in a single nano-
device capable of specifically targeting breast cancer cells. However, native GO sheets have large 
dimensions (0.5-5 m) such that tumor accumulation after a systemic administration is usually 
precluded. Herein, we report a step-by-step synthesis of folic acid-functionalized PEGylated GO, 
henceforth named GO-PEG-Fol, with small size and narrow size distribution (~30±5 nm), and the 
ability of efficiently converting NIR light into heat. GO-PEG-Fol consists of a nano-GO sheet, obtained 
by fragmentation of GO by means of non-equilibrium plasma etching, fully functionalized with folic 
acid-terminated PEG2000 chains through amidic coupling and azide-alkyne click cycloaddition, which 
we showed as active targeting agents to selectively recognize breast cancer cells such as MCF7 and 
MDA-MB-231. The GO-PEG-Fol incorporated a high amount of doxorubicin hydrochloride (Doxo) (> 
33%) and behaves as NIR-light-activated heater capable of triggering sudden Doxo delivery inside 
cancer cells and localized hyperthermia, thus provoking efficient breast cancer death. The cytotoxic 
effect was found to be selective for breast cancer cells, being the IC50 up to 12 times lower than that 
observed for healthy fibroblasts. This work established plasma etching as a cost-effective strategy to 
get functionalized nano-GO with a smart combination of properties such as small size, good 
photothermal efficiency and targeted cytotoxic effect, which make it a promising candidate as  
photothermal agent for the treatment of breast cancer. 
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1. Introduction 
Breast cancer (BC) is the most common disease in women and current drug therapies are far from 
optimal.[1]
 
Many severe side effects arise from therapeutic strategies to treat BC, sometimes combined 
with low effectiveness and poor bioavailability once cancer metastasizes.[2,3] This because cancer 
treatments rely on the use of drugs whose inherent antineoplastic effect is directly related to the way by 
which it is distributed and delivered into specific body districts.[4,5] Drug delivery systems could 
affect drug bioavailability, distribution and toxicity, thereby ensuring a key role in developing more 
selective and efficient cancer treatments.[6] Besides, considerable attention is being focused on smart 
nanomedicines which combine photothermal therapy and targeted drug delivery, as they are multieffect 
tools to overcome drug resistance shortcoming.[7–9]They are photosensitizing agents able to enter 
cancer cells to generate heat from near-infrared (NIR) light absorption, yielding to photothermal 
ablation of solid tumors coupled with selective drug release inside cancer cells. Among these, graphene 
oxide-based nanomedicines are endowed with a combination of biological and optical properties 
potentially useful to deliver high amounts of anticancer drugs to the site of action and, simultaneously, 
act as photosensitizer to increase the anticancer efficacy of these compounds.[10–12]  
From a chemical standpoint graphene oxide (GO) is a monoatomic layer of sp
2
 hybridized carbons 
statistically sp
3 
hybridized and functionalized with oxygen-containing functional groups on its surface 
(epoxy, hydroxyl and carboxyl groups) which serve as precursors for further derivatization, which 
enables the use of bioactive molecules (e.g., targeting agents, prodrugs and antibody) leading to 
enhanced tumor tissue retention without any noticeable toxic effect.[13–15] In fact, to avoid undesired 
heating of healthy cells, surface functionalization of GO with targeting agents such as biotin or folic 
acid would lead to selective uptake in breast cancer cells overexpressing specific receptors instead of 
normal cells in healthy tissues. GO has attracted great attention in the development of cancer 
nanomedicine because of its ability to not only improve the loading and pharmacokinetic of anticancer 
drugs, but also to release the drug payload at a controlled rate by light-activated photothermal 
processes.[16–20] The release of a high localized dose of active compounds inside tumors avoids the 
aforementioned limitations associated with the poor bioavailability and, as consequence, the multidrug 
resistance phenomena.[10,21,22]  
Among materials currently under investigation with high potential as photothermal agents in the NIR 
region, including gold nanorods, carbon nanotubes and carbon nanodots, GO has been recently proven 
able to play itself an essential role in the inhibition of cancer cells propagation in vitro.[23–27] It has 
been showed that GO induces membrane destabilization and oxidative stress in cancer cells leading to 
apoptosis as well as the potential to act as a chemo-sensitizer for cancer cell treatment, since it 
provokes autophagy in mouse CT26 cancer cells by activating toll-like receptors.[28–30] Besides, 
Zhou et al. have found that poly(ethylene oxide)-functionalized GO (PEG-GO) can trigger the 
downregulation of many mitochondrial proteins which inhibits breast cancer metastasis in vivo.[31] 
The awareness of these literature data led us to suppose that GO nanosheets bearing PEG2000 chains and 
folic acid pendants, used as active targeting agent, might selectively enter breast cancer cells 
overexpressing folic acid receptors (FRs) to release the drug payload in a NIR-sensitive fashion, and 
synergistically perform its inherent anticancer effect to provoke tumor death. Herein, we  developed 
nano-sized GO with narrow size distribution, and highly functionalized with PEG chains bearing folic 
acid as end-chain. The GO nano-flakes were obtained by the fragmentation of common GO flakes 
(~0.5-5 m length) via low vacuum plasma etching, affording dimension of about 30 nm. The potential 
as anticancer agent in targeted photothermal therapy was established on MCF7, MDA-MB-231 and 
HDFa cell lines, used as breast cancer and healthy cells, respectively. 
2. Materials and methods 
2.1  Materials 
Doxorubicin hydrochloride (Doxo), N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC-HCl), 4-pentynoic acid (CC), copper (II) 
sulfate pentahydrate, ascorbic acid (99%), folic acid (99%) and poly(ethylene glycol) bis(amine) Mw 
2,000 were purchased from Sigma Aldrich. The reagents were of analytic grade and used as received. 
Graphene oxide (GO) was purchased from ACS Material (USA) and used after purification by dialysis 
tube with nominal molecular weight cut off 10
6
 Da. SpectraPor dialysis tubing was purchased from 
Spectrum Laboratories, Inc. (Italy). 
1
H NMR spectra were recorded using a Bruker Avance II 300 spectrometer operating at 300.12 MHz.  
Size exclusion chromatography (SEC) was carried out using Tosho Bioscience TSK-Gel G4000 PWXL 
and G3000 PWXL columns  connected to a Water 2410 refractive index detector. The mobile phase 
was a 0.1 M Tris buffer pH 8.10± 0.05 with 0.2 M sodium chloride. The flow rate was 0.8 mL min
−1
 
and sample concentration 3 mg mL
-1
 and PEG standards (100-0.400 kDa, Polymer Laboratories Inc., 
USA) were used to set up calibration curve (R
2
 = 0.996).  
Human fibroblasts (HDFa), breast cancer MCF-7 and MDA-MB-231 cells (purchased from Istituto 
Zooprofilattico Sperimentale della Lombardia e dell’ Emilia Romagna, Italy) were grown in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% v/v Fetal Bovine Serum (FBS), 2 mM L-
glutamine, 100 units/mL penicillin G, 100 µg/mL streptomycin at 37°C and 5% CO2. 
2.2 Synthesis of folate-PEG-4-pentynoic acid derivative (Fol-PEG-CC) 
Amino-PEG-Folate (NH2-PEG-Fol) (200 mg) was obtained as reported elsewhere and solubilized in 
ultrapure water (10 mL).[16] To this solution in turn 4-pentynoic acid (13.6 mg, 0.139 mmol) and, 
subsequently, EDC-HCl (26 mg, 0.139 mmol) and NHS (16.0 mg, 0.139 mmol) were added with 
vigorous stirring. The pH of the reaction was adjusted to 6.4 and maintained for 45 minutes. After this 
time, the reaction was kept at room temperature for 18h. Then the heterobifunctional Fol-PEG-CC was 
separated from by-products through gel filtration chromatography (Sephadex ® G15, ultrapure water as 
eluent, flow 1.2 mL min
-1
). Yield 89%.  
1
H NMR (300.15 MHz, MeOD-d4): H 2.09 ( 1H, s, -CCHalkyne), 2.51 (4H, br., -COCH2CH2CH-), 2.19 
– 2.60 (6H, m, -CONHCH2CH2NH- and -OCOCH2CH2NH-), 2.84 (4H, br., -CH2CH2CCH ), 3.74 
(183H, s, OCH2PEG2000 and -OCH2CH2OCO-), 6.68 (2H, m, m-CHfolic acid aromatic ring), 7.63 (2H, m, 
o-CHfolic acid aromatic ring), 8.76 (1H, s, CHfolic acid heteroaromatic ring) 
Size exclusion chromatography (SEC): MW = 2560, Mn = 2150, PD = 1.19 
2.3 Synthesis of GO-N3 nanoflakes 
Graphene oxide (20 mL, 7.5 mg mL
-1
) was added to a solution of sodium azide (135 mg, 2.08 mmol) in 
water (13 mL) and the pH was adjusted to 8.5±0.1 using 1 N sodium hydroxide. The dispersion was 
kept at room temperature for 1h and then freeze-dried.[32] The crude powder was treated with nitrogen 
plasma (1W, 15 cps, 10 rpm, 10
-2 
mbar) for 40 min. After that, the powder was immediately dispersed 
in ethanol/water 75:25 by sonicating for 5 minutes (3 times) and maintained at room temperature for 
18h. Then the dispersion was sonicated for 3h in an ice bath, diluted to 150 mL with water and filtered 
through a syringe filter with cut off 5 m. Yield: 89%. 
2.4 Synthesis of PEG-Folate functionalized GO nanoflakes (GO-PEG-Fol) 
The dispersion of GO-N3 nanoflakes previously obtained (10 mL, 10 mg mL
-1
) was added dropwise 
with stirring to an aqueous solution of NH2-PEG-Fol (200 mg; 0.098 mmol) at pH 6.4. EDC (25 mg, 
0.130 mmol) and NHS (14.96, 0.130 mmol) were then added at once and the pH kept within 6.2-6.5 for 
4 h under sonication in an ice bath (17-22 °C). Then the reaction proceeded for 18 h at room 
temperature with stirring. After that it was sonicated for 2 h in an ice bath. Finally, in turn Fol-PEG-CC 
(Mw = 2391; Mn = 2152; 200 mg; 0.087 mmol), ascorbic acid (10 % w/w) and copper (II) sulfate (5% 
w/w) were added. After 6 h the reaction was dialyzed through a membrane with cut off 25 k and the 
product retrieved as brown slurry. Yield 81% 
2.5 Atomic force microscopy (AFM) of GO-PEG-Fol 
AFM imaging was carried out as previously reported.[17] A drop of a suspension of GO-PEG-Fol in 
ultrapure water (10
-4
 mg mL
-1
) was deposited onto a mica disk and then dried under vacuum (20 mbar) 
overnight. AFM measurements were performed in Tapping mode by a Bruker Dimension FastScan 
microscope equipped with closed-loop scanners and using a FastScan A probes (resonance frequency = 
1400 kHz, tip radius = 5 nm).  
Furthermore, in order to study the etching kinetics, for the GO-N3 samples AFM measurements were 
recorded before and after 120 and 240 minutes from the treatment with nitrogen plasma. 
2.6 Scanning Electron Microscopy (SEM) Analysis 
To study the morphology of the GO-PEG-Fol nanoflakes the freeze-dried sample was observed using a 
FEI Quanta 450 Scanning Electron Microscope. Samples were deposited on a double sided adhesive 
tape previously applied on a stainless steel stub. GO-PEG-Fol nanoflakes were then sputtered with gold 
prior to microscopy examination. 
2.7. Raman spectroscopy 
MicroRaman measurements have been carried out by a Horiba LabRam HR-Evolution multiline 
spectrometer employing the 532 nm laser excitation. A drop of the given GO solution was deposited on 
an Al plate and after solvent evaporation at room temperature measurements have been carried out. The 
laser power was fixed at 0.1 mW, to avoid sample modification, and the spectral resolution was 7 cm
-1
. 
The area investigated by the single measurement using a 100x magnification objective was 1 m2. 
2.8 Dynamic light scattering (DLS) measurements and -potential analysis 
DLS analyses and  -potential measurements (mV) were performed at 25° C using a Malvern Zetasizer 
NanoZS instrument, fitted with a 532 nm laser at a fixed scattering angle of 173°. Either GO-PEG-Fol 
or Doxo-loaded GO-PEG-Fol nanoflakes (0.2 mg mL
-1
) was dispersed in ultrapure water by sonicating 
and filtered through a 5 m cellulose membrane syringe filter before performing the analysis. The Z-
average and polydispersity index (PDI) were obtained by cumulates analysis of the correlation 
function. The -potential (mV) was calculated from the electrophoretic mobility using the 
Smoluchowski equation and assuming that Ka >> 1 (where K and a are the Debye–Hückel parameter 
and particle radius, respectively).[33] 
2.9 Evaluation of the hyperthermic effect of GO-PEG-Fol nanoflakes 
A dispersion of GO-PEG-Fol nanoflakes in water (20 mL, 0.5mg mL
−1
) was prepared and treated with 
a 810 nm diode laser (GBox 15A/B by GIGA Laser) with the power fitted at either 0.5 or 1.4 W cm
-3
. 
At fixed intervals the temperature of the dispersion was recorded and reported as a function of the 
exposure time. The same experiment was carried out on Milli-Q water as blank. 
2.10 Drug loading and drug release kinetics 
The amount of doxorubicin loaded in GO-PEG-Fol/Doxo was determined spectrophotometrically, 
extracting Doxo from the GO-PEG-Fol/Doxo (4 mg) with 0.1 M phosphate buffer at pH 7.4 (20 ml) by 
sonicating and measuring the absorbance of the extract at 480 nm. The amount of Doxo was calculated 
using a calibration curve obtained from standard solutions of Doxo in 0.1 M phosphate buffer at pH 7.4 
(concentration range from 10
-4
 to 0.5 mg mL−
1
; R
2
 = 0.999). The content of doxorubicin was expressed 
as the amount of loaded doxorubicin hydrochloride per unit mass of nanosystem, and resulted to be 
33.3 ±0.3%. 
For the drug release studies in artificial medium, GO-PEG-Fol/Doxo (3.0 mg) was dissolved in PBS at 
pH 7.4 (5 mL) and placed into a dialysis tubing with a MWCO 2 kDa. It was then immersed into PBS 
at pH 7.4 (40 mL) and incubated at 37 °C under continuous stirring (100 rpm) in a Benchtop 808C 
Incubator Orbital Shaker model 420, for 48 h. Aliquots of the external medium (1 mL) were withdrawn 
from the outside of the dialysis tubing at scheduled time intervals and replaced with equal amount of 
fresh medium. The amount of Doxo released was evaluated measuring the absorbance of each sample 
as above described. The cumulative release was determined as a function of incubation time. Drug 
release experiments were also carried out using PBS pH 5.5. All release data were compared with the 
diffusion profile of doxorubicin hydrochloride alone (0.5 mg) obtained by using the same procedure. 
Data were corrected taking in account the dilution procedure. Results were reported as average values 
of three different experiments and in agreement within ±5% standard error. The hyperthermia-triggered 
drug release was evaluated treating a suspension of GO-PEG-Fol/Doxo previously incubated for 4 h in 
PBS pH 7.4 with a 810 nm laser (power fitted at 7 × 10−
2
 W mm−
3
) for 200 s and comparing the release 
values with that observed for the untreated control after an incubation time of 4 h in PBS pH 7.4. 
2.11 In vitro cytotoxicity study of GO-PEG-Fol/Doxo 
The cytotoxicity of GO-PEG-Fol/Doxo was assessed by the MTS assay on human breast cancer cell 
lines (MCF-7 and MDA-MB-231) and healthy human fibroblast (HDFa) using a commercially 
available kit (Cell Titer 96 Aqueous One Solution Cell Proliferation assay, Promega). Cells were 
seeded in a 96-multiwell plate at a density of 1 × 10
4
 cells/well and grown in DMEM. After 24h, the 
medium was replaced with 200 μL of fresh culture medium containing GO-PEG-Fol/Doxo at different 
concentrations, corresponding to equivalent concentrations of Doxo of 0.1, 0.5, 1, 2.5, 5 and 10 μM. 
After 24 and 48 h, samples were withdrawn from the wells and replaced with fresh medium (100 μL) 
and 20 μL of a MTS solution. Cells were incubated for additional 2 h at 37 °C, and then the absorbance 
at 490 nm was measured using a microplate reader (Multiskan, Thermo, U.K.). Free Doxo solutions at 
the same concentrations were used as a positive control, as pure cell medium was used as a negative 
control. Additional experiments were accomplished to evaluate the hyperthermic effects of GO 
nanoflakes. In particular, HDFa, MCF7 and MDA-MB-231 cell lines were incubated with either GO-
PEG-Fol/Doxo or free Doxo for 24 h and then were irradiated with a 810 nm laser beam for 200 sec. 
After the laser treatment, DMEM was removed, cells washed up twice with DPBS and cells viability 
evaluated by MTS assay as above-described. Laser treated cells were used as a negative control. 
Moreover, LIVE/DEAD Cell Viability Assays (Thermo Fischer) was carried out on cells lines treated 
with 5 μM of DOXO or equivalent amount of GO-PEG-Fol, and images were recorded by a 
fluorescence microscope using an Axio Cam MRm (Zeiss). 
Results were expressed as percentage reduction of the control cells. All culture experiments were 
performed in triplicates.  
2.12 Cell uptake study of GO-PEG-Fol on healthy and breast cancer cell lines 
The cellular uptake of GO-PEG-Fol nanoflakes was assessed by fluorescent microscopy (Zeiss “AXIO 
Vert. A1” Microscope Inverted) on HDFa, MCF-7 and MDA-MB-231 cells (2.5 × 104 cells/well) 
cultured for 24 h. [34] Briefly, each well was treated with 500 μL of fresh DMEM containing 5 μM 
Doxo or equivalent amount of GO-PEG-Fol/Doxo and cells were incubated for 2-4-6-24 h. Thus, the 
medium was removed, the cell monolayer was washed twice with PBS pH 7.4, and the nuclei were 
stained with 4′,6-diamidino-2-phenylindole (DAPI). Images were recorded by a fluorescence 
microscope using an Axio Cam MRm (Zeiss). Untreated cells were used as negative control to set the 
auto fluorescence. 
2.13 In vitro wound healing assay (cell migration test) 
The ability of GO-PEG-Fol/Doxo to reduce cell migration was evaluated by the scratch assay. A 
monolayer of either HDFa, MCF-7 and MDA-MB-231 was cultured in 48-well plates at a density of 5 
× 10
4
 cells/well for 48h, and then a wound space was created with a p200 pipet tip. Cells were washed 
up with DMEM to remove the debris and smooth the edge and then incubated with 5 μM Doxo or 
equivalent amount of GO-PEG-Fol/Doxo. Untreated cells were used as positive control. After 24 and 
48 h of incubation cells were washed with PBS pH 7.4 and micrographs were taken with an optical 
microscope equipped with a digital camera (Axio Cam MRm, Zeiss). The cell-to-cell gap was 
measured using Zeiss acquisition software.  
 
3. Results and discussion 
3.1 Synthesis of folate-PEG-4-pentynoic acid derivative (Fol-PEG-CC) 
In recent past, PEGylation strategy has attracted much attention in the field of surface chemistry 
applied to nanomedicine, due to its biocompatibility, solubility and flexibility that induce stability and 
stealth properties to drug delivery systems in the blood compartment. In fact, PEGylation allows 
avoiding the interaction between blood elements and the surface of the coated systems, thus promoting 
higher biocompatibility and long bloodstream circulation owing to the limited capture by the 
mononuclear phagocyte system (RES) [35]. Here, in order to prepare nano-sized GO flakes with 
PEGylated surface, heterobifunctional polyethylene oxides (PEGs) (Mw = 2100, PD = 1.34) bearing 
folic acid at one end and propargylacetic (Fol-PEG-CC) or amine (Fol-PEG-NH2) group at the other 
end-chain were employed.  Folic acid was chosen as active targeting agent, since it has been widely 
demonstrated his capability to bind, with high affinity, FA receptors overexpressed in several human 
carcinomas such as ovary, breast, colon, lung, brain, and endometrium cancers.[36] [37] Whereas 
PEG2000 was selected because it is a discrete high mobile macromolecule that generates large volume 
exclusion that limits unspecific protein adsorption in vivo and proven able to allow specific recognition 
of targeting agents introduced as end-chain.[38] The alkyne-terminated PEG-Fol was exploited to 
functionalize both faces of GO-N3 by the click reaction between azides of GO-N3 and alkyne end chain 
of Fol-PEG-CC, while the amine-teminated PEG was introduced at the GO perimeter by the coupling 
reaction between carboxyl groups of GO-N3 and the amine function of the PEG chains.  
The synthesis of the Fol-PEG-CC was carried out  by two synthetic steps with isolation and purification 
of the NH2-PEG-Folate intermediate  (Scheme 1). In the first step the bis-amino-PEG, with a molecular 
weight of 2 kDa (PD = 1.28), was functionalized at one end-chain with folic acid by amidic bond using 
EDC and NHS as activating agents. An excess of folic acid (1.2 eq.) was used to avoid the presence of 
the unreacted telechelic product so as to facilitate the work up. Under these reaction conditions both the  
 
Scheme 1. Schematic representation of the synthetic pathway employed for the synthesis of Fol-PEG-
CC. 
telechelic product of bis-addition and the semitelechelic product of interest (NH2-PEG-Fol) are formed 
proportionally to the amine/carboxyl acid ratio used.[39]  The molar ratios used allowed obtaining 90 
% of the mono-functionalized derivative on a molar basis. NH2-PEG-Fol was isolated after purification 
by SEC using a G15 resin able to efficiently separate semitelechelic PEG chains from other by-
producs. The hypothesized structure of NH2-PEG-Fol was confirmed by 
1
H NMR spectroscopy (Figure 
1). In particular, the characteristic resonances at 6.68-8.76 ppm of the proton of the folic acid aromatic 
and heteroaromatic rings, together with the shift of the proton resonances at 2.19-2.60 ppm ascribable 
to the terminals, suggest a successful derivatization of PEG chains at the end-chain. Moreover, the 
derivatization degree of folic acid, calculated by comparing the normalized integrals of the peaks at 
6.68 ppm with that at 3.74 ppm, was found to be 2.26% on a molar basis (1:45 repeating units), 
consistent with a PEG molecule functionalized only at one end-chain.  
 
Figure 1. 
1
H NMR (300.15 MHz) spectrum of the NH2-PEG-Fol in MeOD-d4  
In the second step the NH2-PEG-Fol intermediate was derivatized with an alkyne group, and in 
particular with propargylacetic acid, with the aim of obtaining a heterobifunctional PEG able to react 
orthogonally with the azide groups present on the surface of the graphene oxide synthesized, instead of 
with the carboxylic functions at the GO perimeter. With this in mind, the amine group of NH2-PEG-Fol 
was conjugated with the carboxylic group of propargylacetic acid using EDC and NHS as coupling 
agents. In this reaction the likelihood that PEG-PEG cross-coupling occurred, due to the presence of 
the folate free carboxylic group, was negligible. In fact, the extremely high steric hindrance of the 
alpha carboxylic acid in the folate residue provides poor reactivity and, coupled with the high 
competition caused by the use of excess of propargylacetic acid (2 eq.), allowed yielding to exclusive  
formation of the heterobifunctional PEG of interest (Fol-PEG-CC). The structural identification of Fol-
PEG-CC was attained by 
1
H NMR. Apart from the typical groups of resonances observed for the parent 
compound, the alkyne hydrogen resonance at 2.09 ppm confirmed the functionalization of the amine 
end-chain with the alkyne moiety. The derivatization degree in propargylacetic acid was calculated 
comparing the integral of the methine proton (1H) observed at 2.09 ppm with that of the protons 
noticed at 3.74 ppm, attributable to the methylene of the PEG repeating units (176H). This was 2.21% 
on a molar basis (1:45 repeating units), the same observed for the other end-chain (folic acid), in 
agreement with the structure expected for the heterobifunctional Fol-PEG-CC macromolecule.  
3.2 Synthesis and characterization of GO-PEG-Fol nanoflakes 
PEGylation of GO usually involves the coupling reaction between their outside carboxylic functions 
with compounds containing amines such as polyamines, polyampholytes or proteins. However, in such 
nanosystems both faces remain largely free to adsorb proteins in vivo, which is reflected in a low 
biocompatibility. In addition, the low derivatization degree in targeting agents arisen from these high 
localized reactions usually limits water stability in physiological fluids and impede an efficient 
receptor-mediated cell uptake, thus a successful targeted cancer therapy can be jeopardized. In 
principle, the epoxy groups of the GO surface can be used for covalent bonding and hence to obtain 
highly PEGylated GO nanoflakes. Here, GO (monolayer of 500 nm length) was treated with sodium 
azide to open the epoxide function obtaining the GO-N3. Hence, the azide groups introduced on GO 
surface can selectively react with alkyne-functionalized polymers by means of 1-3 dipolar 
cycloaddition (Scheme 2).  
 Scheme 2. Synthesis of the graphene oxide-Polyethylene glycol-Folate (GO-PEG-Fol). 
The reaction was carried out both by thermal processes, with a reflux, and by a solvent free reaction. 
The highest degree of conversion was achieved using the solvent free reaction conditions.[40] In 
particular, the graphene oxide was mixed with sodium azide, and then water was removed by freeze-
drying. Under these conditions, sodium azide is able to react with the epoxides exposed on the surface 
of the GO allowing a good functionalization, as confirmed by the presence of the typical band at 2168 
cm
-1
 in the infrared spectrum (S1). 
Nano-sized GO-N3 flakes were obtained via plasma etching, using nitrogen plasma in a capacitive 
reactor operating at low vacuum. Being slightly corrosive, nitrogen plasma is able to etch GO sheets 
thus reducing original dimensions. Figure 1 shows AFM micrographs of the GO-N3 derivative before 
(Fig. 2a) and after the plasma treatment (Fig. 2b-c). AFM micrographs displayed that the plasma 
treatment induces the formation of grooves in the center of GO-N3 flakes and the formation of small 
fragments of GO-N3 of about 30 nm (Fig. 2b). The reaction evolves over 240 minutes after the plasma 
treatment to lead to nano-flakes of about 30-40 nm width and 1 nm thickness (Fig. 2c), attributable to 
GO-N3 monolayers with narrow size distribution. 
 
Figure 2. AFM micrographs of the pristine GO-N3 (a) and the nitrogen plasma-treated GO-N3 after 120 
min (b) and 240 min (c) from the treatment.  
The Raman measurements reported in Figure 3 evidences that no relevant changes in the GO structure 
are induced by the plasma treatments up to 120 minute. In details, both the D,G spectral region around 
1500 cm
-1
 and the 2D region at about 2900 cm
-1
 feature the typical bands of GO with negligible 
amplitude and position modifications.[41] 
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Figure 3. Raman measurements of the GO-N3 before and after nitrogen plasma treatment up to 120 
min. 
The GO-N3 nanoflakes were further derivatized with Fol-PEG-CC and NH2-PEG-Fol to obtain a 
nanosystem endowed with high stability in physiological fluids and capability of actively recognizing 
tumor cells. The greater stability of the nanosystem was achieved by means of a full PEGylation of 
both the perimeter and the two mirror faces of the GO-N3 nanoflakes (Scheme 2). While the perimeter 
of the GO-N3 nanoflakes bears carboxylic acid functions capable of reacting with the amine groups of 
NH2-PEG-Fol upon activation with EDC and NHS, both planar faces contain azide groups able to 
chemo-selectively react with the alkyne group of Fol-PEG-CC. It was not necessary to purify the 
product before carrying out the latter reaction step, since the 1,3-dipolar cycloaddition reaction and the 
amide coupling reaction were completely orthogonal, obtaining a pure product with high yields (Yield 
= 98%).   
 
 Figure 4. Absorption spectra (a) and FT-IR spectra (b) of GO-PEG-Fol and the parent compounds 
A reliable investigation of GO-PEG-Fol structure is by no means trivial, and therefore we used many 
spectroscopic and microscopic methods to assess the feasibility of the reactions. Figure 4 a depicts the 
UV spectra obtained for GO-PEG-Fol compared to those of the intermediates. Both GO-N3-PEG-Fol 
and GO-PEG-Fol sample displayed the typical absorption bands of NH2-PEG-Fol at 200, 275 and 355 
nm. Furthermore, the contribution of the folic acid bands was much more for the GO-PEG-Fol sample, 
which confirms the higher derivatization degree of this nanostructure owing to the complete 
functionalization of both GO faces. It is noteworthy that the NIR absorption tails for the GO samples 
increased over the degree of functionalization in folic acid, implying higher photothermal conversion 
for the GO-PEG-Fol sample. The covalent functionalization of GO-PEG-Fol was also studied by FTIR 
(Figure 4b). The GO-N3-PEG-Fol spectrum was characterized by some diagnostic vibrations ascribable 
to GO sheets, such as those at 3300 cm
-1
 (OH and H2O stretching), 1750 cm
-1
 (C=O stretching), 1668 
cm
-1
 (C=C stretching) and 1611 cm
-1
 (asymmetric COO
-
 stretching), together with typical bands of 
CONH-PEG-Fol moiety located at 2880 cm
-1
 (O-CH2- stretching ) and 1615 cm
-1
 (CONH  stretching), 
implying that PEG-Fol moieties are covalently linked to the GO sheets. Besides, not significant 
changes in the mode of vibrations were observed at 2168 cm
-1
 (azide group), suggesting that the 
derivatization with PEG-Fol occurred along the flake's perimeter between carboxilyc groups of GO and 
amine functions of NH2-PEG-Fol. The disappearance of the latter vibration in the GO-PEG-Fol 
spectrum, combined with more marked PEG-Fol bands, clearly showed that a further covalent 
functionalization of GO-N3-PEG-Fol involved the reaction of alkyne groups of Fol-PEG-CC and azide 
functions of GO-N3-PEG-Fol. This is also a good evidence that PEGylation occurred regioselectively at 
both GO surfaces.  
The functionalization of GO sheets with PEG-Fol chains was also established by means of AFM and 
SEM microscopies (Figure 5). Figure 5a shows a typical dimensional distribution analysis of GO-PEG-
Fol, where the presence of GO islands with a thickness of about 3.5 nm and a diameter of about 40 ± 4 
nm can be observed. The increase of the nano-flakes thickness of about 2.5 nm can be explained with a 
homogeneous functionalization of the GO surface with Fol-PEG-CC chains of 2.5 kDa, corroborating 
UV and FTIR data.[5,42] It might be noticed that the small size and the narrow size distribution 
observed are suitable for biomedical applications, especially as carrier for anticancer drugs, since nano-
carriers with dimensions between 20-50 nm allow enhanced in vivo bioavailability and tumor 
accumulation, thereby improving the effectiveness of anticancer treatments. 
  
Figure 5. AFM measurement and size distribution (a) and SEM micrograph (b) of GO-PEG-Fol. 
SEM analysis of GO-PEG-Fol reported in Figure 5b displayed unilamellar GO sheets with the 
characteristic structure observed in the native GO flakes, nevertheless exhibiting a roughness 
attributable to the PEG chains deposited onto the GO surface. On the whole, AFM and SEM data 
corroborated the hypothesis that GO-PEG-Fol is a fully PEGylated GO carrying covalently linked PEG 
chains both on the edge and on the surface. 
3.3 Physicochemical Properties. 
3.3.1. Photothermal conversion of the GO-PEG-Fol.  
One interesting property of GO is the capability of giving rise to local heating after near infrared (NIR) 
laser stimulation. This behavior has been recently exploited for the physical eradication of solid tumors 
through photothermal therapy and for the photo-triggered local release of high amount of anticancer 
agents [10,17,18,43,44]. This is a minimally invasive technique, which uses hyperthermia, intended as 
a local rise in temperature into the tumor mass (usually to 40−45 °C), generated by energy transfer 
produced during the irradiation of GO with a light of wavelength in the NIR region, to kill selectively 
cancer cells. Therefore, the ability of GO-PEG-Fol to convert a NIR energy source into heat was 
evaluated by applying an 810 nm laser beam with variable power density (0.5 and 1.4 W cm
-2
) for 300 
sec and by measuring the temperature of the dispersions (Figure 6). As a rule, the temperature linearly 
increased over the laser exposure time both at 0.5 and 1.4 W cm
-2
, reaching a maximum of 44.5 °C 
after 300 sec at the higher power density employed. A remarkable power-dependent trend was 
observed. In fact, the temperature increased about two times faster for the sample irradiated with the 
higher power density. However, the photothermal conversion of GO-PEG-Fol, reported as normalized 
differential temperature increase (°C cm
3
 W
-1
), followed a non-obvious direction (Figure 6). In 
particular, the photothermal conversion was about twice bigger at low power density. This can be 
explained considering that, at the same concentration, the amount of independent harmonic oscillators 
which determine modes of vibrations in GO-PEG-Fol are stochastically saturated at lower power 
density, thereby limiting further thermal dissipation of excess energy. Overall, obtained data show that 
the functionalization of GO with PEG-Fol did not affect the photothermal properties of the virgin GO, 
since GO-PEG-Fol is still able to cause sudden and efficient heating when stimulated by a laser source 
at 810 nm. Accordingly, these data seem to suggest that the nanosystems have photothermal 
characteristics suitable for in vivo phototherapy of solid tumors.  
 
Figure 6. Photothermic behavior of GO-PEG-Fol nanoflakes in water at concentration of 0.5 mg mL
−1
: 
temperature (left ordinate) and photothermal efficiency (right ordinate) as function of the exposure time 
at increasing power density (0.5 and 1.4 W cm
-2
)  
3.3.2. Drug loading and drug release studies.  
GO nanoflakes are interesting drug carriers because both sides of a single nano-sheet could be 
accessible for drug binding, offering interesting properties from a technological and pharmaceutical 
point of view. The high specific surface area and the highly sp2 hybridized structure of GO lead to 
strong π-π, hydrogen and hydrophobic interactions with aromatic drugs affording to simple adsorption. 
Many anticancer drugs such as doxorubicin possess aromatic portions useful for their reversible 
adsorption on GO surfaces, thereby ensuring a gradual and stimuli-sensitive release in the site of action 
to gain a local therapeutic effect with negligible toxic off-target effects.[45] Therefore, here, the GO-
PEG-Fol nano-flakes were loaded reversibly with doxorubicin, used as a model anticancer drug, by 
simply mixing the drug with the nanosystem under sonication. The Doxo loading was evaluated 
spectrophotometrically by extracting the drug and measuring the absorbance at λ 480 nm. Results are 
reported in Table 1.  
Table 1. Physiochemical  characterization of  the GO-PEG-Fol and GO-PEG-Fol/Doxo 
Sample 
a
Size 
 (nm) 
a
Thickness  
(nm) 
a-Potential 
(mV) 
c
Drug loading  
(w/w %) 
Loading efficiency  
(w/w %) 
GO-PEG-Fol 35 1.25 -28 n.d. n.d. 
GO-PEG-Fol/Doxo 40 1.3 -5 33.3 98.6 
a
 Obtained by AFM analysis  
b 
Obtained by DLS analysis 
c 
Obtained by spectrophotometric analysis 
It is interesting to notice that almost all Doxo incubated whit GO nanoflakes was absorbed, obtaining a 
drug loading of 33.3 % (w/w) with a loading efficacy of 98.65 %, one of the highest observed in the 
literature.[46] The ability of GO-PEG-Fol nano-flakes to adsorb Doxo was also confirmed by ζ-
potential measurements. The reduction of the ζ-potential value (from -28 to -5 mV) observed for the 
GO-PEG-Fol/Doxo sample indicated that the cationic form of Doxo electrostatically interacted with the 
native negative charges of GO-PEG-Fol (Table 1), allowing short-range π-π stacking.  
The release profile of Doxo was studied using either PBS pH 7.4 or acetate buffer pH 5.5, which 
mimicked normal physiological medium and the tumour microenvironment, respectively. The study 
was carried out by equilibrium dialysis experiments, quantifying the amount of released doxorubicin in 
the external medium at scheduled time intervals and until 48 h (Figure 7). The drug release from GO-
PEG-Fol/Doxo was compared to the diffusion profile of free Doxo, used as a control. Figure 7 shows 
that the diffusion of free drug at both pH values was not dependent on the medium and 100% of drug 
diffuses into the receiving compartment within 5 h.  
 
Figura 7. Drug release kinetics of GO-PEG-Fol/Doxo obtained at 37°C in PBS pH 7.4 and acetate 
buffer pH 5.5: the diffusion profile of free Doxo is reported as control experiments. The NIR-triggered 
drug release after 4h of incubation is reported on the right (power density = 7 × 10−
2
 W mm−
3
). 
GO-PEG-Fol/Doxo nanoflakes released their payload in a time-dependent fashion, without the burst 
effect observed for the free drug. Data also shows that only the 15 % of drug payload was released at 
pH 7.4 after 48 h of incubation, indicating good stability of the system upon administration, avoiding 
the premature drug release before reaching the target site. On the contrary, GO-PEG-Fol/Doxo released 
doxorubicin more quickly in acidic condition (~ 27 %), showing a remarkable pH-dependent release 
profile. One can speculate that, being GO-PEG-Fol highly carboxylated, the protonation of carboxylic 
groups in acidic condition lead the partial dissociation of hydrogen bonding with Doxo molecules, 
which can freely diffuse throughout the tumour microenvironment.[47] Moreover, as the selective 
release of the drug payload can be in principle controlled photothermally by means of external NIR 
light stimuli, we also assessed the hyperthermia-triggered release after 4h of incubation (Figure 7, 
insert on the right).[10,48,49] This strategy is proposed to improve the selectivity of the treatment 
reducing toxic side effects. It can be noticed that just after 300 sec of laser treatment at low power 
density the nanosystem promptly released 100 % of its drug payload, indicating that the GO-PEG-
Fol/Doxo can act as a technological platform capable of triggering simultaneously highly localized 
hyperthermia and on-demand drug release inside the tumour site. Hence, our nanosystem could be 
employed to gain synergistic and non-invasive photothermal effects to avoid drug resistance 
phenomena and efficiently eradicate solid tumours avoiding recidivisms. 
3.3.3. Physicochemical stability of GO-PEG-Fol/Doxo in aqueous media.  
The physicochemical stability of the GO-PEG-Fol/Doxo under physiological conditions was assessed 
both in PBS pH 7.4 and DMEM dispersion, at concentration of 0.1 mg mL
-1
, by evaluating the size 
distribution over time (three days).  
Table 2. Physiochemical stability of  the GO-PEG-Fol/Doxo in aqueous dispersion at 37 °C  
 
a 
Obtained by DLS analysis 
 
Data reported in Table 2 showed that the size distribution of the Doxo-loaded nanosystem did not significantly 
change over time until three days of incubation at 37 °C. Indeed, the average diameter in PBS pH 7.4 passed 
Medium 
a
Size 
(nm) 
 t = 0 t = 24h t = 48h t = 72h 
PBS pH 7.4 48.0 48.2 51.4 64.2 
DMEM 51.1 50.2 54.8 77.6 
from 48 to 64.2 nm, indicating negligible aggregation of the GO nano-sheets. This trend was also observed in 
DMEM, where a slight aggregation was observed maybe due to the adsorption of proteins from the medium onto 
the GO-PEG-Fol surface. However, the original nanometric dimensions of the proposed nanosystem were 
preserved under physiological conditions, indicating a good stability.  
3.4 Biological Characterization of the GO-PEG-Fol/Doxo nanoflakes.  
3.4.1. In vitro cytotoxic effect on cancer and healthy cells.  
The in vitro cytotoxicity of GO-PEG-Fol/Doxo was evaluated on breast cancer cells (MCF7 and MDA-
MB-231) and healthy cells (HDFa), used as model of estrogen response, triple negative breast cancer 
cells and  healthy cells, respectively, so as to evaluate the ability of the nanosystem to preferentially kill 
tumor cells instead of the healthy ones. In particular, to investigate the potential selectivity of GO-
PEG-Fol/Doxo we used HDFa cell line, MCF-7 and MDA-MB-231 breast cancer cell lines as models 
that express variable levels of folic acid receptors (FR) on their cell surface. MDA-MB-231 is a highly 
FR positive human breast adenocarcinoma cell line that overexpresses FRs on their cell surfaces, 
whereas MCF-7 is a low FR expressing human breast adenocarcinoma cell line and HDFa is a normal 
cell line that does not express significant levels of FR on their cell surfaces.  
In a first set of experiments GO-PEG-Fol  was proven cytocompatible toward all cell lines considered 
both after 24 and 48 h of incubation (Figure 8a).  
 Figure 8. Cytocompatibility and in vitro anticancer effect. Cell viability of MCF7 (purple), MDA-MB-
231 (green) and HDFa (blue) treated with GO-PEG-Fol for 24 (solid lines) and 48h (dashed lines) (a). 
Cell viability of HDFa (b), MCF7 (c) and MDA-MB-231 (d) treated with Doxorubicin (purple) and 
equivalent amount of GO-PEG-Fol/Doxo (blue) for 24 (solid lines) and 48 (dashed lines) hours. 
The doxorubicin-loaded GO-PEG-Fol nano-flakes showed negligible cytotoxic effects on healthy 
HDFa, always lower if compared to that observed for equivalent amount of free Doxo (Table 2.: Imax
48h
 
= 40±2.1 vs 45.7±4.2, respectively) (Figure 8b), whereas it displayed excellent antitumor activity 
against both breast cancer cells after 24 and 48 h of incubation (Figure 8c-d). However, GO-PEG-
Fol/Doxo exhibited higher efficacy on MDA-MB-231 (FR+++), killing up to 99.8% of cells after 48 h 
of incubation at the higher concentration considered (10 g mL-1) (Figure 8d). As showed in Tab.2, 
GO-PEG-Fol/Doxo nanoflakes was forty times more efficacy on MDA-MB-231 cell lines, that 
overexpressed FR, compared to MCF7 cell lines (IC50
48h
 ≈0,1vs 3.75M, for MDA-MB-231 and 
MCF7, respectively). This finding hints at a crucial rule of folate-mediated endocytosis mechanisms 
which allows the selective cytotoxic effect observed for cancer cells that overexpress FR. The IC50 
values reported in Table 2 for MCF7 are within the range reported for Doxo-loaded nanomedicines. To 
the best of our knowledge, prior works have reported IC50 from 3.4 to 18.25 g mL
-1
, confirming that 
GO-PEG-Fol/Doxo nanoflakes have high pharmacological potency.[5,10,50] The same consideration 
can be made for MDA-MB-231 cells.[50–52] It is noteworthy that, comparable to the effect caused by 
free Doxo, GO-PEG-Fol/Doxo showed a selective cytotoxicity towards cancer cells, especially for 
MDA-MB-231. In fact, the selectivity index (SI) reported in Table 2, calculated as the ratio between 
the cytotoxic effect observed for cancer cells and HDFa at the maximum dose (Imax
48h
), was 
significantly higher for the nanosystem if compared to that observed for free Doxo (2.5 vs 2.05). 
Despite this, a comparable SI was observed for free Doxo and GO-PEG-Fol/Doxo for MCF7 cells 
(1.78 vs 1.68). Some recent investigations have described doxorubicin‐bound nanomaterials that lead to 
less effective in vitro cytotoxicity on HDFa (i.e., higher IC50), but with lower selectivity index 
(SI<2.15).[10,11,53] This might be correlated to the higher folic acid (targeting agent) density 
displayed from the GO surface in GO-PEG-Fol/Doxo. 
Table 2. Half maximal inhibitory concentration (IC50) and maximum cell growth inhibition (I%) values 
calculated for free Doxo and GO-PEG-Fol/Doxo on HDFa, MCF7 and MDA-MB-231 cell lines. 
Cell lines Sample IC50
24h
 
(M) 
Imax
24h 
(%) 
IC50
48h 
(M) 
Imax
48h 
(%) 
SI 
HDFa 
Doxo >10 17.1±2.5 >10 45.7±4.2 - 
GO-PEG-Fol/Doxo >10 3.1±3.7 >10 40±2.1 - 
MCF7 
Doxo 1.72 66.5±0.9 0.57 76.6±0.3 1.68 
GO-PEG-Fol/Doxo 7.5 55.1±1.8 3.75 71±0.5 1.78 
MDA-MB-231 
Doxo 1.25 56.1±2.3 <0.1 94±1.3 2.05 
GO-PEG-Fol/Doxo >10 48.8±3.9 ≈0.1 99.8±0.2 2.50 
 
3.4.2. In vitro cell uptake study on healthy fibroblasts and breast cancer cell lines.  
With the aim of understanding if the nanosystem is able to enter cancer cells to act at intracellular level, 
we established cell uptake of GO-PEG-Fol/Doxo on HDFa, MCF7 and MDA-MB-231 by fluorescence 
microscopy up to 24 h of incubation. Free Doxo and GO-PEG-Fol/Doxo can be visualized upon cell 
internalization because of their inherent red fluorescence. Whilst bright red fluorescence was localized 
only inside nuclei up to 6 h from the incubation on HDFa, MCF7 and MDA-MB-231 displayed 
additional fluorescence inside cytosol and in the peri-nuclear region (Figure 9). A similar behavior was 
observed after 24 of incubation. On the whole, Figure 9 suggests that GO-PEG-Fol/Doxo enter HDFa 
and cancer cells exploiting different pathways, mainly influenced by the overexpression of FR, thus 
affecting the mode of action. In fact, MDA-MB-231 cells, which overexpress the higher level of FR on 
the cell membrane, are characterized by ubiquitously red fluorescence inside cells implying a different 
biodistribution of the nanosystem inside cells. 
 
Figure 9. Uptake studies of GO-PEG-Fol/Doxo at Doxo concentration of 5μM on HDFa (FR-), MCF7 
(FR++) and MDA-MB-231 (FR+++). Magnification 100x. Scale bar 50 m  
3.4.3. In vitro wound healing assay (cell migration test).  
Migration is a critical characteristic of cancer cells for tumor burden and metastatic outbreak. An 
effective nanomedicine useful in precision cancer therapy should oppose metastasis by limiting cell 
migration towards pre-metastatic niches, and wound healing assay could help us to study that potential 
inclination.[53,54] Cell migration was investigated on monolayered HDFa, MCF7 and MDA-MB-231 
cell cultures incubated for 24 h with free Doxo at a drug concentration of 5μM or equivalent amount of 
GO-PEG-Fol/Doxo. Wound healing was quantified by taking into account the initial cell gap provoked 
by a scratch and the cell gap recovery in 24 h. GO-PEG-Fol/Doxo allowed the wound healing of HDFa 
culture after 24h, whereas free Doxo provided only 27 % healing after 48 h (Figure 10). This is in 
agreement to cell viability data (Figure 8b, Table 2), where a negligible dysfunction of the HDFa 
proliferation abilities was registered after the exposure with the nanosystem, whereas free Doxo 
provoked significant HDFa death. Interestingly, as migration processes were largely inhibited on both 
breast cancer cell lines treated with GO-PEG-Fol/Doxo or free Doxo a sharp decrease of wound 
healing was measured (from 0 to 37 % healing) (Figure 10). However, GO-PEG-Fol/Doxo exhibited 
higher inhibition activity on MDA-MB-231 (FR+++) cells after 48 h incubation (16 % healing), 
providing a good evidence that folic acid residues are key factors to promote Doxo anti-metastatic 
effects at intracellular level. Surprisingly, free Doxo did not elicit any effect on MDA-MB-231 cells.  
 
Figure 10. Wound healing assay at Doxo concentration of 5μM on HDFa, MCF7 and MDA-MB-231 
cell lines by optical microscopy. Magnification 5x: scale bar 20 m.  
3.4.4. In vitro photothermal effect.  
To demonstrate the applicability of the NIR photothermal ablation of cancer cells by means of GO-
PEG-Fol/Doxo, we performed in vitro MTS assay on the healthy HDFa cell line and breast cancer cell 
lines, which overexpress increasing amount of FR on the cell membrane (i.e. MCF7 and MDA-MB-
231, respectively). The cell viability of the HDFa cells treated with either Doxo at a concentration 
range within 0.1 – 10 M or equivalent amount of GO-PEG-Fol/Doxo did not significantly decrease 
after 24 h of incubation (Figure 11 a). The cell viability was found to slightly decrease to about 40% 
(50 and 38 % for the free Doxo and GO-PEG-Fol/Doxo, respectively) when the HDFa cells were also 
treated at the maximum Doxo dose with an 810 nm laser diode for 200 s at low power density (0.2 W 
cm
-2
). This trend is clearly shown in the Live/Dead assay reported in Figure 11 a’-a’’’, where 
fibroblasts appear copious and healthy after the laser treatment both for free Doxo and the nanosystem.  
Things appear different if one looks the effect of the same treatment on both breast cancer cell lines 
(Figure 11 b-b’’’ and c-c’’’). Cell viability sharply decreased with a dose-dependent trend after the NIR 
treatment both for Doxo and GO-PEG-Fol/Doxo on MCF7 and MDA-MB-231 (Figure 11 b and c). 
Although the NIR phototherapy improved free Doxo efficacy the IC50 values remained comparable, 
implying that the pharmacological potency of the free Doxo was not affected by the photothermal 
treatment. On the contrary, the potency of GO-PEG-Fol/Doxo remarkably increased after the NIR 
exposure (IC50 from 8.69 to 0.51 M and from >10 to 1.88 M for MCF7 and MDA-MB-231, 
respectively) (Figure 11 b,c). Besides, as shown in Figure 11 b-b’’’ and c-c’’’ the NIR photothermal 
efficacy of GO-PEG-Fol/Doxo was very higher than that of free Doxo, implying an excellent 
anticancer efficacy of this nanosystem compared to the free drug. In particular, for the GO-PEG-
Fol/Doxo at the maximum dose cell viability reached 10 and 0.6% on MCF7 (Figure 11b) and MDA-
MB-231 (Figure 11c), respectively, whereas the same dose of free Doxo led to cell viability values 
from 1.9 to 50 times higher. This is clearly shown in the Live/Dead experiments reported in Figure 11 
b’-b’’’ and c’-c’’’, where live cell population appeared significantly lower after the NIR treatment on 
both cancer cell lines incubated with GO-PEG-Fol/Doxo (b’’’, c’’’). It is noteworthy that the SI 
calculated for GO-PEG-Fol/Doxo considering photothermal effects (Figure 11 a-c) are about 12 and 
2.3 times higher than that calculated for the free Doxo on MCF7 and MDA-MB-231, respectively. 
Corroborating the hypothesis that this nanosystem could enhance the efficacy of anticancer drugs by 
NIR-triggered localized hyperthermia, minimizing off-target toxic effects.  
 
Figure 11. NIR photothermic effect on HDFa (a-a’’’), MCF7 (b-b’’’) and MDA-MB-231 (c-c’’’) after 
the 810 nm laser exposure for 200 sec at low power density (0.2 W cm
-2
). Cell viability (a, b, c) as 
function of Doxo concentration for free Doxo (red symbols) and GO-PEG-Fol/Doxo (green symbols) 
after 24 h of incubation (solid lines) followed by 810 nm laser treatment for 200 sec (dashed lines). 
Live/dead assay (a’-a’’’; b’-b’’’; c’-c’’’): calcein-AM (green, live), ethidium homodimer-1 (red, dead). 
Magnification 5x: scale bar 100 m.  
4. Conclusions 
GO represents a versatile 2-D carbon nanomaterial which may be promising in different biomedical 
applications due to their biocompatibility, adsorption and photothermal properties. Here, we developed 
nano-sized folic acid-containing PEGylated GO, namely GO-PEG-Fol, as a therapeutic platform to 
combine stimuli-sensitive chemotherapy and photothermal therapy so as to improve breast cancer 
treatments, while reducing off-target side effects. We obtained azide-functionalized GO with small 
average size and narrow distribution, ~30 ±5 nm yielded via low-vacuum plasma etching. Highly folate 
functionalized GO nano-flakes were obtained by combining regioselective azide-alkyne click-
chemistry and amide coupling between heterobifunctional Fol-PEG-alkyne or Fol-PEG-NH2 chains 
with azide or carboxyl groups of GO-N3, respectively. PEGylation of GO nano-flakes provoked 2-fold 
increase in the NIR absorbance and efficient photothermal conversion. Besides, the functionalization of 
GO with folic acid-containg PEG2000 chains provided cancer cell recognition capabilities and allowed 
loading high amounts of Doxo (>33% w/w), making it able to selectively enter and kill breast cancer 
cells overexpressing folic acid receptors. We assessed a selective in vitro photothermal cytotoxic effect 
on breast cancer cells (MCF7 and MDA-MB-231) from 3 to 12 times higher than that measured for 
healthy cells such as fibroblasts. Overall, we showed that GO-PEG-Fol could be exploited as a 
promising photothermal agent at low power density, owing to its targeting property, small size, suitable 
photothermal conversion, and selectivity towards breast cancer cells.  
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